Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
William Fearon MD

William F. Fearon MD

Professor of Medicine and Director of Interventional Cardiology, Stanford University School of Medicine, Stanford, California; Chief, Cardiology Section, VA Palo Alto Health Care Systems, Palo Alto, California

Dr. Fearon graduated from Dartmouth College and received his medical degree from Columbia University College of Physicians and Surgeons, where he was elected into the Alpha Omega Alpha Medical Honor Society. He completed an Internal Medicine residency at Stanford University Medical Center serving an extra year as a Medical Chief Resident. He completed a General Cardiology and Interventional Cardiology fellowship at Stanford, spending his third year as the Chief Cardiology Fellow. He is currently a Professor of Medicine (Cardiology) and Director of Interventional Cardiology at Stanford University School of Medicine and the Chief of the Cardiology Section at the VA Palo Alto Health Care System. Dr. Fearon is board certified in cardiovascular medicine and interventional cardiology, and he is a fellow of the American College of Cardiology, the American Heart Association, and the Society of Cardiovascular Angiography and Interventions. He has been elected to the American Society for Clinical Investigation and the Association of University Cardiologists.

Dr. Fearon’s primary area of research interest is in coronary physiology. He has been the principal investigator of numerous multicenter clinical trials, including the FAME trials, which have resulted in multiple publications in the New England Journal of Medicine and led to worldwide adoption of the use of coronary physiology to guide revascularization decisions in the cardiac catheterization laboratory. He also derived and validated the index of microcirculatory resistance, which is now used commonly to assess coronary microvascular function. He has over 250 publications, speaks regularly at major international conferences, and serves on the editorial board of the Journal of the American College of Cardiology, Circulation, JACC Cardiovascular Interventions, and Circulation: Cardiovascular Interventions, among other journals. His research laboratory has had near continuous NIH funding and he is currently the principal investigator on an NIH grant evaluating cardiac allograft vasculopathy. He has received multiple teaching awards from Stanford University and has mentored numerous clinician-scientists. Dr. Fearon’s clinical activities include not only percutaneous coronary intervention, but also transcatheter aortic valve replacement. 


Dr. Fearon receives research support from Abbott Vascular, Boston Scientific, and Medtronic; consults with CathWorks; and has minor stock options with HeartFlow.